SallyJohnson National Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, United KingdomUnited Kingdom

SallyJohnson
Dr Sally Johnson is the lead paediatric clinician at the UK National Renal Complement Therapeutics Centre, which has a national role in the management of patients with atypical HUS and C3G. She is also a paediatric nephrologist at the Great North Children’s Hospital, UK. She undertook clinical and academic training in the West Midlands, including a PhD in aHUS. She was Chief Investigator of The National Study of MPGN and C3G and of the ECUSTEC trial, a randomised controlled trial of Eculizumab in STEC-HUS. She was Research Secretary for the British Association for Paediatric Nephrology (BAPN) from 2019 to 2022 and is co-chair of the BAPN Clinical Studies Group. She is a member of the Kidney Research UK (KRUK) grants committee.
Institution

Day 3 - Tuesday April 16, 2024

Time Session
12:30 p.m.
1:30 p.m.
New Insights into C3 Glomerulonephritis: Focus on Pathogenesis and Potential Therapeutic Targets
AnujaJava Chairperson WASHINGTON UNIVERSITY SCHOOL OF MEDICINE IN ST. LOUISUnited States
Prof LizLightstone Chairperson Imperial College LondonUnited Kingdom
  • Complement in Kidney Disease: Overview of the Complement Cascade in Kidney Injury
    Peter Zipfel Speaker Peter.Zipfel@hki-jena.deLeibniz Institute for Natural Product Research and Infection BiologyGermany
  • C3 Glomerulopathy: New Developments and Therapeutic Targets
    CarlaNester Speaker carla-nester@uiowa.eduUniversity of IowaUnited States
  • Challenges in Diagnosing C3G
    SallyJohnson Speaker sallyajohnson73@gmail.comNational Renal Complement Therapeutics Centre, Newcastle Upon Tyne Hospitals NHS Foundation Trust, United KingdomUnited Kingdom
  • Q and A
Hall C1